Well covered, growing, and liquid. A quarterly payer at $0.21 a share, $0.84 annualized — and second-quarter FFO as Adjusted of $0.40 a share, a company record, covered the $0.21 dividend at a 53% payout, with same-property NOI up 3.2%, consolidated leased occupancy at 96.6%, and full-year FFO as Adjusted guidance raised $0.02 to $1.50–$1.54 a share. The dividend was raised from $0.19 to $0.21 in March 2026, an 11% increase following a 12% increase in 2025, and $22 million of signed-but-not-yet-open leases represents about 7% of annualized NOI still to come. For a REIT, the House reads FFO payout — never the EPS payout, which depreciation makes meaningless; net income of $0.14 a share in the quarter looks thin only because of that distortion.
Key risk: Retail tenancy and concentration — grocery-anchored centers in the New York and Washington, D.C. metros carry tenant-bankruptcy risk (a Wren Kitchens bankruptcy hit the quarter), and same-property occupancy slipped 40 basis points to 96.3% even as consolidated occupancy rose.
Changes if: FFO as Adjusted payout pushes past ~70%, same-property NOI turns negative, or the signed-not-open rent pipeline stalls. Any of those reopens this grade.
- ✓AFFO coverage check: Second-quarter FFO as Adjusted of $0.40 a share covered the $0.21 dividend at a 53% payout — a wide cushion, and the $1.52 guidance midpoint implies about 55% for the full year.
- ✓Growth check: The dividend rose 11% in March 2026 to $0.21 from $0.19, same-property NOI grew 3.2% in the quarter, new leases on a same-space basis signed at a 12.8% average cash spread, and guidance was raised — growth and coverage are moving together.
- ✓Balance-sheet check: Net debt of about $1.62 billion ($1.70 billion of total debt less $82 million of cash) was 34% of total market capitalization at June 30, 2026, with $957 million of liquidity. No clean net debt-to-EBITDA figure was stated in the second-quarter release, so none is shown here — it was omitted rather than estimated.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.